These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 19150090)
21. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974 [TBL] [Abstract][Full Text] [Related]
22. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease. Helfand BT; Mongiu AK; Kan D; Kim DY; Loeb S; Roehl KA; Meeks JJ; Smith ND; Catalona WJ BJU Int; 2009 Aug; 104(3):304-9. PubMed ID: 19239451 [TBL] [Abstract][Full Text] [Related]
23. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223 [TBL] [Abstract][Full Text] [Related]
24. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614 [TBL] [Abstract][Full Text] [Related]
25. Pathological outcomes of candidates for active surveillance of prostate cancer. Conti SL; Dall'era M; Fradet V; Cowan JE; Simko J; Carroll PR J Urol; 2009 Apr; 181(4):1628-33; discussion 1633-4. PubMed ID: 19233388 [TBL] [Abstract][Full Text] [Related]
26. The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. Boorjian SA; Karnes RJ; Crispen PL; Rangel LJ; Bergstralh EJ; Sebo TJ; Blute ML J Urol; 2009 Jan; 181(1):95-104; discussion 104. PubMed ID: 19012937 [TBL] [Abstract][Full Text] [Related]
27. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Nanda A; Chen MH; Renshaw AA; D'Amico AV Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185 [TBL] [Abstract][Full Text] [Related]
28. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984 [TBL] [Abstract][Full Text] [Related]
29. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. Shepard DR; Dreicer R; Garcia J; Elson P; Magi-Galluzzi C; Raghavan D; Stephenson AJ; Klein EA J Urol; 2009 Apr; 181(4):1672-7; discussion 1677. PubMed ID: 19230915 [TBL] [Abstract][Full Text] [Related]
30. A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy. Miyamoto H; Hernandez DJ; Epstein JI Hum Pathol; 2009 Dec; 40(12):1693-8. PubMed ID: 19683331 [TBL] [Abstract][Full Text] [Related]
36. Effect of body mass index on histopathologic parameters: results of large European contemporary consecutive open radical prostatectomy series. Isbarn H; Jeldres C; Budäus L; Salomon G; Schlomm T; Steuber T; Chun FK; Ahyai S; Capitanio U; Haese A; Heinzer H; Huland H; Graefen M; Karakiewicz P Urology; 2009 Mar; 73(3):615-9. PubMed ID: 19010520 [TBL] [Abstract][Full Text] [Related]
37. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Lane BR; Stephenson AJ; Magi-Galluzzi C; Lakin MM; Klein EA Urology; 2008 Dec; 72(6):1240-5. PubMed ID: 18692874 [TBL] [Abstract][Full Text] [Related]
38. Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy. Chino J; Schroeck FR; Sun L; Lee WR; Albala DM; Moul JW; Koontz BF BJU Int; 2009 Nov; 104(10):1496-500. PubMed ID: 19388991 [TBL] [Abstract][Full Text] [Related]
39. Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. Ronquist G; Frithz G; Wang YH; Lindeborg T Scand J Urol Nephrol; 2009; 43(1):32-6. PubMed ID: 18932051 [TBL] [Abstract][Full Text] [Related]
40. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. Nguyen CT; Reuther AM; Stephenson AJ; Klein EA; Jones JS J Urol; 2009 Jan; 181(1):75-80. PubMed ID: 19012927 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]